FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.1
Mode of action
Fasenra directly binds to IL-5Rα, preventing IL-5 from binding to eosinophils2 .By recruiting natural killers cells via IL-5R⍺, FASENRA actively targets and depletes eosinophils2. FASENRA promotes eosinophil apoptosis without degranulation or the release of eosinophil mediators3.
FASENRA is the only severe asthma biologic that provides rapid, near-complete depletion of blood eosinophils in 24 hours1, 2 ,4